Garnocestim

Drug Profile

Garnocestim

Alternative Names: 251353; SB 251353

Latest Information Update: 30 Nov 2004

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Chemoprotectants; Proteins
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemoprotection

Most Recent Events

  • 30 Nov 2004 Discontinued - Phase-I for Chemotherapy induced damage (Prevention)/Chemoprotection in USA (unspecified route)
  • 12 Dec 2003 This compound is still in active development
  • 06 Apr 2001 A study has been added to the Haematological Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top